Citi upgrades Bristol-Myers Squibb (NYSE: BMY) from Hold to Buy.

Citi analyst says, "We project three-year incremental pharmaceutical revenue ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE